Virologica Sinica

, Volume 33, Issue 2, pp 201–204 | Cite as

Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine

  • Fan Luo
  • Fan-Lu Liao
  • Hui Wang
  • Hong-Bin Tang
  • Zhan-Qiu Yang
  • Wei Hou

Dear Editor,

In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in Guangdong Province, China, infected more than 8000 individuals, and resulted in a 10% mortality rate (Rota et al.2003). Later, in 2012, a novel CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), was isolated from the sputum of a man in Saudi Arabia (Perl et al.2014). Notably, MERS-CoV recently reemerged in the Republic of Korea, and killed 36 out of 186 confirmed cases (Korea Centers for Disease Control and Prevention 2015). Therefore, SARS-CoV still carries the potential for resurgence; efforts are being made to prevent the recurrence of an epidemic.

Currently, effective antiviral strategies to control SARS-CoV infections are lacking; vaccination is still regarded as the major approach for preventing SARS and related diseases. Generally, virus-specific antibodies play important roles in the control of viral infections. However, the presence of specific antibodies can be beneficial for...



This work was supported by the Chinese Medicine Foundation and Opening Foundation of State Key Laboratory of Virology, Wuhan University (No. 2016KF010).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest to disclose.

Animal and Human Rights Statement

All of the study protocols and procedures were approved by the Institutional Animal Care and Use Committee of Wuhan University.

Supplementary material

12250_2018_9_MOESM1_ESM.pdf (331 kb)
Supplementary material 1 (PDF 332 kb)


  1. de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM (2014) Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog 10:e1004386CrossRefPubMedPubMedCentralGoogle Scholar
  2. Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R (2008) Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 133:45–62CrossRefPubMedGoogle Scholar
  3. Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daëron M, Bruzzone R, Peiris JS (2011) Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J Virol 85:10582–10597CrossRefPubMedPubMedCentralGoogle Scholar
  4. Jolly PE, Weiss HL (2000) Neutralization and enhancement of HIV-1 infection by Sera from HIV-1 infected individuals who progress to disease at different rates. Virology 273:52–59CrossRefPubMedGoogle Scholar
  5. Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, Chu SL, Tse J, Guarner J, Zaki SR, Subbarao K, Peiris M, Nal B, Altmeyer R (2007) Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 25:729–740CrossRefPubMedGoogle Scholar
  6. Korea Centers for Disease Control and Prevention (2015) Middle east respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect 6:269–278CrossRefPubMedCentralGoogle Scholar
  7. Luo F, Hou W, Yang ZQ, Tang ZJ, Wang Y, Xian QY, Sun LH (2007) Intratracheal inoculation of severe acute respiratory syndrome coronavirus in monkeys Macaca rhesus. Acta Virol 51:171–177PubMedGoogle Scholar
  8. Perl TM, McGeer A, Price CS (2014) Medusa’s ugly head again: from SARS to MERS-CoV. Ann Intern Med 160:432–433CrossRefPubMedGoogle Scholar
  9. Qin E, Shi H, Tang L, Wang C, Chang G, Ding Z, Zhao K, Wang J, Chen Z, Yu M, Si B, Liu J, Wu D, Cheng X, Yang B, Peng W, Meng Q, Liu B, Han W, Yin X, Duan H, Zhan D, Tian L, Li S, Wu J, Tan G, Li Y, Li Y, Liu Y, Liu H, Lv F, Zhang Y, Kong X, Fan B, Jiang T, Xu S, Wang X, Li C, Wu X, Deng Y, Zhao M, Zhu Q (2006) Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 24:1028–1034CrossRefPubMedGoogle Scholar
  10. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497Google Scholar
  11. Roberts A, Lamirande EW, Vogel L, Jackson JP, Paddock CD, Guarner J, Zaki SR, Sheahan T, Baric R, Subbarao K (2008) Animal models and vaccines for SARS-CoV infection. Virus Res 133:20–32CrossRefPubMedGoogle Scholar
  12. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Peñaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Günther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394–1399CrossRefPubMedGoogle Scholar
  13. Takano T, Kawakami C, Yamada S, Satoh R, Hohdatsu T (2008) Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. J Vet Med Sci 70:1315–1321CrossRefPubMedGoogle Scholar
  14. Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen KH, Liu FT, Liu WT, Chen YM, Huang JC (2014) Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 451:208–214CrossRefPubMedGoogle Scholar
  15. Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY (2005) SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 23:4959–4968CrossRefPubMedGoogle Scholar
  16. Yip MS, Leung NH, Cheung CY, Li PH, Lee HH, Daëron M, Peiris JS, Bruzzone R, Jaume M (2014) Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol J 11:82CrossRefPubMedPubMedCentralGoogle Scholar
  17. Zhou J, Wang W, Zhong Q, Hou W, Yang Z, Xiao SY, Zhu R, Tang Z, Wang Y, Xian Q, Tang H, Wen L (2005) Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23:3202–3209CrossRefPubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.State Key Laboratory of Virology/Hubei Province Key Laboratory of Allergy and Immunology/Institute of Medical Virology, School of Basic Medical SciencesWuhan UniversityWuhanChina
  2. 2.Department of Clinical Laboratory, Zhongnan HospitalWuhan UniversityWuhanChina
  3. 3.Center for Animal Experiment/Animal Biosafety Level-III LaboratoryWuhan UniversityWuhanChina

Personalised recommendations